Viridian Therapeutics, Inc. VRDN
30.60 USD +0.11 (+0.38%)
Nov 13, 2026, 2:29 PM EST
29.81 Day range 30.77
13.18 52-week range 34.29
- YTD
- -1.69%
- 1 year
- +7.39%
Held by funds
131 US ETFs and mutual funds hold VRDN · largest positions
Ownership
Held by insiders 0.17%
Held by institutions 123.95%
Float held by institutions 124.16%
Institutions 314
Top institutional holders
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 15.42% | 17,509,137 | 533.68M | Sep 29, 2026 |
| Blackrock Inc. | 7.53% | 8,551,488 | 260.65M | Jun 29, 2026 |
| Bellevue Group AG | 5.93% | 6,731,909 | 205.19M | Jun 29, 2026 |
| Paradigm Biocapital Advisors LP | 5.92% | 6,723,788 | 204.94M | Jun 29, 2026 |
| Kynam Capital Management, LP | 5.68% | 6,453,877 | 196.71M | Jun 29, 2026 |
| State Street Corporation | 5.39% | 6,124,976 | 186.69M | Jun 29, 2026 |
Top mutual fund holders
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.94% | 3,336,970 | 101.71M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.28% | 2,590,081 | 78.95M | Sep 29, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 2.20% | 2,495,461 | 76.06M | Sep 29, 2026 |
| Fidelity Advisor Series VII-Fidelity Advisor Biotechnology Fund | 1.81% | 2,058,130 | 62.73M | Sep 29, 2026 |
| Fidelity Select Portfolios-Select Health Care Portfolio | 1.32% | 1,500,000 | 45.72M | Sep 29, 2026 |
| T. Rowe Price Health Sciences Fund, Inc. | 1.27% | 1,447,742 | 44.13M | Jun 29, 2026 |
Insider activity
Open-market buys and sales by officers, directors and 10% owners (SEC Form 4), last 24 months.
- Bought
- $20M
- 1 trade
- Sold
- $316K
- 2 trades
- Net
- +$19.7M
- last 12 months
- Buyers / Sellers
- 1 / 1
- distinct insiders
- Buy
- Sale
- Marker size: that day's dollars · columns: dollars per month
Recent trades
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Aug 19, 2026 | Tousignant Jennifer(Form 4 on SEC.gov) Chief Legal Officer | Sale | 10,000 | 24.50 | $245.00K |
| Aug 14, 2026 | Tripuraneni Radhika(Form 4 on SEC.gov) Chief Medical Officer | Exercise | 40,000 | 13.21 | $528.40K |
| May 11, 2026 | Fairmount Funds Management LLC(Form 4 on SEC.gov) Director, 10 percent owner: | Buy | 1,176,470 | 17.00 | $20.00M |
| Dec 31, 2025 | Tousignant Jennifer(Form 4 on SEC.gov) Chief Legal Officer | Sale | 2,272 | 31.16 | $70.80K |
| Oct 23, 2025 | Fairmount Funds Management LLC(Form 4 on SEC.gov) Director, 10 percent owner: | Buy | 454,545 | 22.00 | $10.00M |
| Jun 10, 2025 | Fairmount Funds Management LLC(Form 4 on SEC.gov) Director, 10 percent owner: | Exercise | 12,500 | 12.31 | $153.88K |
| Jun 9, 2025 | Fairmount Funds Management LLC(Form 4 on SEC.gov) Director, 10 percent owner: | Exercise | 1,600 | 7.80 | $12.48K |
Insiders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BEETHAM THOMAS W | Chief Operating Officer | Conversion of Exercise of derivative security | Mar 2, 2026 | 13,361 |
| FAIRMOUNT FUNDS MANAGEMENT LLC | Beneficial Owner of more than 10% of a Class of Security | Purchase | May 10, 2026 | 0 |
| HARMON SETH | Chief Financial Officer | Conversion of Exercise of derivative security | Mar 2, 2026 | 7,790 |
| MAHONEY STEPHEN F | Chief Executive Officer | Conversion of Exercise of derivative security | Mar 2, 2026 | 33,349 |
| TOUSIGNANT JENNIFER | Officer | Sale | Aug 18, 2026 | 0 |
| TRIPURANENI RADHIKA | Officer | Conversion of Exercise of derivative security | Aug 13, 2026 | 40,000 |